Kishnani, P., Lachmann, R., Mozaffar, T., Walters, C., Case, L., Appleby, M., … Landy, H. (2019). Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. In Molecular Genetics and Metabolism (Vol. 126, pp. S85–S86). Elsevier BV. https://doi.org/10.1016/j.ymgme.2018.12.211

Kishnani, Priya, Robin Lachmann, Tahseen Mozaffar, Crista Walters, Laura Case, Matt Appleby, Vincenzo Libri, Manisha Kak, Marie Wencel, and Hal Landy. “Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease.” In Molecular Genetics and Metabolism, 126:S85–86. Elsevier BV, 2019. https://doi.org/10.1016/j.ymgme.2018.12.211.

Kishnani P, Lachmann R, Mozaffar T, Walters C, Case L, Appleby M, et al. Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. In: Molecular Genetics and Metabolism. Elsevier BV; 2019. p. S85–6.

Kishnani, Priya, et al. “Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease.” Molecular Genetics and Metabolism, vol. 126, no. 2, Elsevier BV, 2019, pp. S85–86. Crossref, doi:10.1016/j.ymgme.2018.12.211.

Kishnani P, Lachmann R, Mozaffar T, Walters C, Case L, Appleby M, Libri V, Kak M, Wencel M, Landy H. Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. Molecular Genetics and Metabolism. Elsevier BV; 2019. p. S85–S86.